Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Q3 Revenues Decline 31 Percent as Net Loss Nearly Doubles

NEW YORK, Nov. 2 (GenomeWeb News) - Ciphergen Biosystems yesterday reported a 31-percent decline in third-quarter revenue and almost doubled losses as sales of its ProteinChip mass spectrometry systems and BioSepra process chromatography products took a hit.

 

Revenues for the quarter ended Sept. 30 totaled $11 million, down from $16 million during the same period last year.

 

R&D expenses declined to $4.7 million from $5.4 million during the year-ago quarter.

 

Ciphergen's loss for the quarter widened to $9.5 million, or $.33 per share, almost twice as much as last year's loss of $5.2 million, or $.18 per share, during the third quarter.

 

As of Sept. 30, Ciphergen had $19 million in cash, cash equivalents, and investments in securities.


Last week, the company said it will sell its BioSepra business to Pall for $32 million.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.